Anthracycline Global Market Report 2026

Anthracycline is a group of potent chemotherapy drugs derived from specific types of Streptomyces bacteria. These drugs function by disrupting the DNA (deoxyribonucleic acid) of cancer cells, inhibiting their growth and replication, and are used to treat a variety of cancers, including breast cancer, lymphomas, leukemia, and others.

The main drugs in the anthracycline class include daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Daunorubicin is an anthracycline chemotherapy drug that blocks DNA and RNA synthesis by intercalating into the DNA helix and inhibiting topoisomerase II, resulting in cell cycle arrest and apoptosis in rapidly dividing cells. These drugs are available in various dosage forms, including powder, capsules, solutions, injections, suspensions, and others, and are used to treat conditions such as acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bladder cancer, breast cancer, and more. The end users include hospitals, home care settings, specialty clinics, and others.

Tariffs have impacted the anthracycline market by increasing the cost of active pharmaceutical ingredients and finished formulations, particularly affecting global supply chains reliant on cross-border manufacturing. The impact is most pronounced in injectable dosage forms and liposomal drug segments, with Asia-Pacific and Europe being highly affected due to their strong role in API production and oncology drug exports. Hospitals and specialty clinics face pricing pressures that can influence procurement decisions and treatment accessibility. However, tariffs have also encouraged local manufacturing, regional sourcing, and domestic production capabilities, creating long-term opportunities for supply chain resilience and market self-sufficiency.

The anthracycline market research report is one of a series of new reports from The Business Research Company that provides anthracycline market statistics, including anthracycline industry global market size, regional shares, competitors with a anthracycline market share, detailed anthracycline market segments, market trends and opportunities, and any further data you may need to thrive in the anthracycline industry. This anthracycline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthracycline market size has grown strongly in recent years. It will grow from $1.6 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to growing prevalence of breast cancer and hematological malignancies, established clinical efficacy of anthracyclines, widespread adoption in standard chemotherapy protocols, increasing hospital-based chemotherapy administration, early regulatory approvals of key anthracycline drugs.

The anthracycline market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in liposomal and targeted drug delivery, rising cancer incidence in emerging economies, increasing investment in oncology drug development, expansion of outpatient and specialty oncology clinics, growing demand for cost-effective generic chemotherapy drugs. Major trends in the forecast period include development of liposomal anthracycline formulations, rising focus on cardiotoxicity reduction strategies, expansion of anthracycline use in combination therapies, increased adoption of generic anthracycline drugs, optimization of dosing regimens for improved tolerability.

The rising prevalence of cancer is expected to drive the growth of the anthracycline market in the coming years. Cancer comprises a group of diseases that can develop in nearly any organ or tissue when abnormal cells grow uncontrollably, breach their usual boundaries, and either spread to other organs or invade surrounding tissues. Anthracyclines, a class of chemotherapy drugs, play a crucial role in cancer treatment by inhibiting cell division through disruption of DNA structure and function. For instance, in September 2025, the American Cancer Society, a US-based professional organization, reported that an estimated 313,780 new cases of prostate cancer are expected in the United States in 2025. The risk of developing prostate cancer increases sharply with age, rising from 0.2% in men under 50 to 6.5% in those aged 70-79. Therefore, the growing prevalence of cancer is fueling the expansion of the anthracycline market.

Major companies in the anthracycline market are focusing on developing innovative products, such as non-cardiotoxic formulations, to enhance the safety profile of chemotherapy treatments. Non-cardiotoxic formulations are drugs or therapies designed to minimize or eliminate heart damage, particularly the adverse effects often associated with certain chemotherapy drugs, including anthracyclines, which can result in heart failure or other cardiac complications. For instance, in April 2024, the European Medicines Agency, a Netherlands-based regulatory agency, granted Orphan Drug Designation to Annamycin, a next-generation anthracycline, for the treatment of acute myeloid leukemia (AML). This designation provides significant incentives for developing therapies for rare diseases, including seven years of market exclusivity after approval, preventing other manufacturers from marketing the same drug for the same indication. Additional benefits include tax credits covering up to 50% of clinical trial costs, waivers of application fees, and regulatory guidance from the FDA, all designed to reduce the financial burden associated with developing drugs for small patient populations.

In August 2023, CNX Therapeutics Limited, a UK-based specialty pharmaceutical company, acquired four cancer support products-Cardioxane (dexrazoxane), Savene (dexrazoxane), Totect (dexrazoxane), and Ethyol (amifostine)-from Clinigen Limited for an undisclosed amount. Cardioxane is indicated for adults with advanced or metastatic breast cancer to prevent long-term cardiac damage from certain anthracyclines. Savene is used to treat anthracycline extravasation, a rare condition in cancer patients, while Totect addresses both anthracycline extravasation and cardiovascular protection associated with doxorubicin in women with metastatic breast cancer. Clinigen Limited is a UK-based pharmaceutical services company that supplies commercial medicines for clinical study use.

Major companies operating in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm USA LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Asia-Pacific was the largest region in the anthracycline market in 2025. The regions covered in the anthracycline market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthracycline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthracycline market consists of sales of aclarubicin and pixantrone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthracycline Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses anthracycline market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthracycline ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anthracycline market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drugs: Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Valrubicin
• 2) By Dosage: Powder; Solution; Injection; Other Dosages
• 3) By Application: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Bladder Cancer; Breast Cancer; Other Metastatic Cancers
• 4) By End User: Hospitals; Specialty Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Novartis AG; Bristol-Myers Squibb Company; Fresenius SE & Co. KGaA; Merck & Co. Inc.; Zydus Lifesciences Limited; Viatris Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Limited; Gland Pharma Limited; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Endo Pharmaceuticals Inc.; Amneal Pharmaceuticals Inc.; Zhejiang Hisun Pharmaceutical Co. Ltd.; Accord Healthcare Limited; Athenex Inc.; Miracalus Pharma Pvt. Ltd.; Transo-Pharm USA LLC; BluePoint Laboratories; Areva Pharmaceuticals Inc.; GeneraMedix Inc.; Salius Pharma Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.